Article
Pharmacology & Pharmacy
Ryuichi Kambayashi, Ai Goto, Hiroko Izumi-Nakaseko, Ichiro Oikawa, Naoki Ikeda, Kazuki Matsuda, Yoshinori Takei, Akio Matsumoto, Yuji Kumagai, Atsushi Sugiyama
Summary: This study investigated the impact of a lack of placebo control on the interpretation of results in thorough QT/QTc (TQT) studies. The analysis showed that the lack of placebo control did not influence the interpretation of TQT study results in both central-tendency and concentration-response analyses, in line with the updated E14/S7B Q & As.
JOURNAL OF PHARMACOLOGICAL SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Eric I. Rossman, Todd A. Wisialowski, Hugo M. Vargas, Jean-Pierre Valentin, Michael G. Rolf, Brian M. Roche, Steve Riley, Michael K. Pugsley, Jill Nichols, Dingzhou Li, Derek J. Leishman, Robert B. Kleiman, Andrea Greiter-Wilke, Gary A. Gintant, Michael J. Engwall, Annie Delaunois, Simon Authier
Summary: The ICH E14/S7B Questions and Answers (Q&As) guideline introduces the concept of a double negative nonclinical scenario to demonstrate no clinical QT prolongation and recommends best practices for robust nonclinical cardiovascular telemetry studies.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
(2023)
Article
Pharmacology & Pharmacy
Hugo M. Vargas, Eric I. Rossman, Todd A. Wisialowski, Jill Nichols, Michael K. Pugsley, Brian Roche, Gary A. Gintant, Andrea Greiter-Wilke, Robert B. Kleiman, Jean-Pierre Valentin, Derek J. Leishman
Summary: Recent updates and modifications to the clinical ICH E14 and nonclinical ICH S7B guidelines provide an opportunity for nonclinical in vivo electrocardiographic (ECG) data to directly influence clinical strategies and regulatory decisionmaking. More robust nonclinical in vivo QTc datasets based on standardized protocols and best practices can reduce variability and optimize QTc signal detection, enhancing their value for clinical QTc risk assessment.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
(2023)
Article
Pharmacology & Pharmacy
Yasushi Orihashi, Yuji Kumagai
Summary: The relationship between drug concentration and QTc interval is typically evaluated using a mixed effects model that includes baseline QTc interval as a covariate. When two or more baselines are observed for a subject, including baseline mean as a covariate in the model shows higher accuracy and power in concentration-QTc analyses compared to models without baseline adjustment. This model assumes a specific covariance structure in QTc intervals that approximates the correlations within and between days.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
(2021)
Article
Pharmacology & Pharmacy
Michael K. Pugsley, Yevgeniya E. Koshman, Michael Foley, Brett R. Winters, Simon Authier, Michael J. Curtis
Summary: This editorial introduces the annual themed issue on safety pharmacology methods published in the Journal of Pharmacological and Toxicological Methods since 2004. It highlights the content derived from the recent joint meeting of the Safety Pharmacology Society and the Canadian Society of Pharmacology and Therapeutics in Montreal, Canada. The meeting generated 179 abstracts, which are included in the current volume of the journal. The manuscripts reflect various areas of innovation in safety pharmacology, including the comparison of different study designs for QTc assessment, the use of hiPSC neuronal cell preparations for neuropharmacological safety screening, and the evaluation of inotropic adversity using hiPSC derived cardiac myocytes.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
(2023)
Article
Biochemical Research Methods
Kris King, Pei Li, Alicia Pietrasiewicz, Stanley Goldstein
Summary: Bioanalysis plays a crucial role in generating data for drug development, regulated by local agencies and global organizations to ensure data integrity and quality. Major regulatory agencies and organizations are updating industry guidance for bioanalytical method validation to keep pace with new technologies and regulations, which has sparked some controversies.
BIOMEDICAL CHROMATOGRAPHY
(2021)
Article
Oncology
Ruijun Ji, Yanfang Liu, Xinyu Liu, Linlin Wang, Dandan Wang, Wenjuan Wang, Runhua Zhang, Ruixuan Jiang, Jiaokun Jia, Hao Feng, Zeyu Ding, Gaifen Liu, Jingjing Lu, Yi Ju, Xingquan Zhao
Summary: Among the 5 models for predicting SAP after ICH, the ICH-APS-B showed the best predictive performance, suggesting it may be a useful tool for implementing personalized care of patients and conducting clinical trials of SAP after ICH.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Medical Informatics
Lian Gelis, Isabelle Stoeckert, Hans-Peter Podhaisky
Summary: In recent years, the pharmaceutical industry has embraced digital technologies, such as digital health technology (DHT), to enhance the drug development process and product marketing. While both the US-FDA and the EMA support technological advancements, the regulatory environment in the US appears to be more conducive to innovation in the digital health sector. On the other hand, the new Medical Device Regulation imposes strict requirements on the regulatory scrutiny of Medical Device software. Regardless of its status as a Medical Device, a digital tool used in clinical drug trials must meet basic safety and performance requirements, adhere to quality system and surveillance requirements, and comply with GxP and local data privacy and cybersecurity regulations. Harmonization of regulatory requirements and consistent development of the regulatory landscape between the US and the EU could further promote the use of digital tools in drug clinical development, with promising prospects in the use of digital tools in clinical trials.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE
(2023)
Article
Medical Informatics
Maurizio Massella, Diego Alejandro Dri, Donatella Gramaglia
Summary: This article investigates the use of machine learning tools in clinical trials and their link with trustworthy artificial intelligence principles in the decision-making process. Potential issues are identified, and areas of attention are highlighted. This research is important for further supporting the evaluation of medicinal products developed using data-driven tools in clinical trials.
HEALTH AND TECHNOLOGY
(2022)